PaxMedica, Inc. Common Stock
PXMD · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.02 | -0.11 | -0.00 |
| FCF Yield | -855.40% | -34.21% | -9.53% | -4.78% |
| EV / EBITDA | 0.21 | -0.97 | -7.97 | -8.66 |
| Quality | ||||
| ROIC | -415.56% | -4,819.35% | 90.74% | 150.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.59 | 0.41 | 0.54 | 0.30 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -77.37% | -10.13% | -134.70% | -460.08% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | 0.10 | 0.06 | 0.09 |
| Interest Coverage | -1,761.59 | -2,024.82 | -2.57 | -9.13 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |